Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

On the path to profitable growth

Bio-Works Technologies Q3-2022 update Today, Bio-Works Technologies AB reported sales for the third quarter 2022, yet another strong quarter with product sales amounting to 7.2 MSEK, an increase of +51% as compared to the same period in the previous year. So far this year, Bio-Works net sales have grown by 94% to 25.3 MSEK. The company’s order book grew to 16.1 MSEK from 11.1 MSEK on June 30.”We are very happy with the Q3 results. Net sales are in line with our expectations,” said Jonathan Royce, CEO at Bio-Works.The North American market continues to grow fastest (+369% vs 3Q21) and the

Notification of managers’ and closely related parties’ transactions with Dampskibsselskabet NORDEN A/S’ shares in connection with share buy-back program

ANNOUNCEMENT NO. 216 - 21 OCTOBER 2022  In connection with the announced share buy-back program in NORDEN, A/S Motortramp continuously sells shares pro rata and the market is to be informed accordingly – see the attached file and announcement no. 158/22. A/S Motortramp participates in NORDEN’s share buy-back program by selling shares pro rata in order to maintain the current ownership of just under 32% of the shares in NORDEN.     Kind regards, Dampskibsselskabet NORDEN A/S   Martin Badsted CFO     For further information: Thomas France, Investor

BioStock: Evaxion brings in Per Norlén as CEO

With the recently initiated phase IIb trial in melanoma, Evaxion Biotech has entered a new, advanced clinical development phase with its portfolio of AI-driven immunotherapies. The company is ready to build a solid commercial profile and pursue strong partnerships to bring its products to market to help millions of cancer patients worldwide. A significant step in that direction was appointing industry veteran Per Norlén to the CEO position. BioStock reached out to the new CEO and Evaxion’s Chair of the Board, Marianne Soegaard, to learn more about this important transition for the company.

Nomination committee appointed ahead of 2023 Annual General Meeting of Fractal Gaming Group AB (publ)

In accordance with the decision of the Annual General Meeting (AGM), Fractal Gaming Group´s nomination committee shall consist of the three largest shareholders as of September 30 and the Chairman of the Board. Fractal Gaming Group hereby announces that the nomination committee has now been appointed ahead of the AGM 17 May, 2023. The nomination committee consists of the following members:Carl-Mikael Lindholm, appointed by Herenco HoldingLars Verneholt, appointed by Litorina IV L.P.Daniel Johnsson, appointed by Långholmen Holding ABMagnus Yngen, Chairman of the Board, Fractal

Calliditas Therapeutics’ nomination committee composition for the AGM 2023

Calliditas Therapeutics AB (publ.) publishes the nomination committee’s composition for the AGM in 2023.The nomination committee, which is appointed in accordance with the principles adopted by the extraordinary general meeting in 2017, consists of: • Patrick Sobocki, appointed by Stiftelsen Industrifonden • Karl Tobieson, appointed by Linc AB • Jan Särlvik, appointed by Fjärde AP-fonden • Elmar Schnee (chairman of the board of directors) The nomination committee shall, before the annual general meeting 2023, prepare a proposal for the election of chairman and other members

Brighter’s warrants of series TO9 are admitted to trading

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, NEW ZEALAND, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. The rights issue of shares and warrants in Brighter AB (publ) (“Brighter” or the “Company”) was registered at the Swedish Companies Registration Office on October 17, 2022. The warrants of series TO9 will be trading on Nasdaq First North Growth Market, starting October 28, 2022, under the ticker “BRIG TO9” with ISIN-code SE0018537862. The

One RescueRunner system ordered to French Fire Rescue Services

We are very pleased to announce that another Fire Rescue Services department in France have ordered a RescueRunner system.Through our French distributor Fire Technologies Eurl, another Fire Rescue Service department in France order a RescueRunner system. The Fire Rescue Service department will primarily use the new RescueRunner for increased water rescue capacity in the event of floodings and on inland waters in the area. The RescueRunner system is a very flexible and efficient boat system that can operate in shallow and inaccessible waters and crucial for the Fire Rescue Service

BioStock: PHI expands market potential with regenerative medicine opportunity

Phase Holographic Imaging’s sales have doubled in one year, according to the company’s annual report published this week. However, it generates even more confidence for the company because PHI now addresses the entire spectrum of the healthcare market, not just medical research. The company aims to become a welded link in the value chain of modern medicine in general and regenerative medicine in particular. To find out more, BioStock contacted the company’s CFO, Patrik Eschricht.Read the interview with PHI's CFO Patrik Eschricht at biostock.se: PHI expands market potential with

Data show OXC-201 may be a promising treatment for allergic asthma.

A new study, Pharmacological OGG1 inhibition decreases murine allergic airway inflammation, was published 17[th] of October in Respiratory pharmacology, Frontiers in Pharmacology, (DOI 10.3389/fphar.2022.999180, Tanner L, Bergwik J, Bhongir RKV, Pan L, Dong C, Wallner O, Kalderén C, Helleday T, Boldogh I, Adner M and Egesten A) and demonstrates that Oxcia’s potential clinical candidate OXC-201 (TH5487) may be a promising treatment for allergic asthma.Allergic asthma is a complex inflammatory disease characterized by wheezing, dyspnea, coughing, chest tightness and variable airflow

Invitation to presentation of Humana's report on third quarter 2022

Humana's interim report for the third quarter and nine-month period 2022 results will be published at 08:00 CET on November 10, 2022. A web-cast telephone conference will be held at 09:00 CET the same day.The webcast, where CEO and President Johanna Rastad will present the report, will be accessible at Humana's website www.humanagroup.com. The presentation material will be published on the website before the conference starts. The webcast, and later the recorded version of the webcast, will also be available at www.financialhearings.com.  To participate in the conference call, and

Publishing of Stockmann’s Interim Management Statement for January–September 2022

STOCKMANN plc, Press release 21.10.2022 at 10:00 EET Stockmann plc will publish its Interim Management Statement for January–September 2022 on Friday, 28 October 2022 at 8:00 a.m. EET. A press and analyst briefing will be held in English the same day at 10:00 a.m. EET in the Stockmann Lounge on the 4A floor in Stockmann’s Helsinki city centre department store, entrance from the F staircase on the Pohjoisesplanadi side. The event can also be followed as a live webcast by this link . The recording and presentation material will be available on

Getinge to support the American Heart Association in progressing care for cardiogenic shock patients

Today, Getinge announces its support of the American Heart Association initiative to build a Cardiogenic Shock Registry. This unparalleled initiative will enable a wide range of cardiogenic shock research, based on patient data from hospitals across the US, and lead to opportunities to promote best practices and improve clinical outcomes. Historically, data related to cardiogenic shock has been limited, inconsistent, and challenging to interpret. If not treated quickly, cardiogenic shock can lead to organ failure and death. Even when treated timely and at specialized centers, the

BioStock: ClearPoint Neuro delivers first order to CLS

Following the FDA clearance of Clinical Laserthermia Systems’ MR-guided laser ablation system in neurosurgery, US commercialisation was swiftly initiated. The commercialisation is led by the medtech’s global distributor ClearPoint Neuro. On Monday, CLS could announce that their efforts have already paid off in the form of a first order worth 5,5 million SEK. BioStock reached out to CLS’ CEO Dan Mogren for a comment.Read the article at biostock.se: https://www.biostock.se/en/2022/10/clearpoint-neuro-delivers-first-order-to-cls/ This is a press release from BioStock - Connecting

Formpipe signs a multi-year agreement with the Danish Board of Agriculture to a business value of approximately DKK 80-100 million.

The Danish Board of Agriculture (Landbrugsstyrelsen) has carried out a procurement regarding continued operation and development of one of the agency's administrative systems. Formpipe has been chosen as the main supplier in a service agreement where Formpipe's responsibility includes development and system maintenance. The assignment is performed in collaboration with Capgemini as a subcontractor with responsibility for system support.The agreement runs over four years with options to extend with additional three years, and the order value amounts to a minimum of DKK  7 million in the form

Nokian Tyres: Disclosure under chapter 9, section 10 of the securities market act

Nokian Tyres plc Stock Exchange Release October 21, 2022 at 9:50 a.m. Nokian Tyres has received an announcement from BlackRock, Inc. on October 20, 2022, in accordance with the Finnish Securities Market Act Chapter 9, Section 5. According to the announcement, the indirect holding in Nokian Tyres shares owned by BlackRock, Inc. and its funds fell below the level of 5% of the share capital of Nokian Tyres plc, as a result of share transactions concluded on October 19, 2022. Total positions of BlackRock, Inc. and its funds subject to the notification: +----------------+----------+-----

I-Tech AB (publ) Interim report Q3 2022

I-Tech AB (publ) (ticker: ITECH) publish the interim report for the third quarter 2022 Click here on the 21 October 2022 at 10:30 to follow the webcast  Click here to go to I-Tech's Financial Reports Summary of the period” Strong growth with Asia as the driving force ” •    Net sales for the period amounted to 21,277 (13,811) kSEK, which corresponds to a sales increase of 54 (16)%. Operating profit amounted to 4,802 (837) kSEK. July to September 2022•    No

Wirtek ends acquisition process

Company Announcement no. 14/202221 October 2022   This announcement contains inside information After finalising the due diligence process of the potential acquisition announced on 14 July 2022 (see company announcement no. 11/2022 ), the Board of Directors have at this time decided not to continue the acquisition process.   Wirtek will as planned publish the interim report for Q3 2022 on 9 November 2022.   Further information · Michael Aaen, CEO, Wirtek A/S, Phone: +45

QUARTERLY REPORT, THIRD QUARTER 2022

Press release: Stockholm, October 21, 2022, 08.45 CET HIGHLIGHTS OF THE THIRD QUARTER 2022 · Net sales was 66 MSEK compared to the previous year 83 MSEK. The decrease was due to declined silver price and lower production · EBITDA was -10 MSEK (13) · EBIT was -32 MSEK (-9) · Cash and cash equivalents were 7 MSEK (48).  The Company has a credit limit of EUR 1.5 million. The Company initiated the process to consider options to raise additional funding · Investments were 17 MSEK (10) · The production was about 258 000 (308 000) ounces of silver, 790 (839)

Flerie Invest invests heavily in life science

In the past year, investment company Flerie Invest has almost doubled the number of life science companies in its portfolio, which currently holds about 30 companies. A driving factor is that the man behind the company – Thomas Eldered – sold his entire holding in the successful company Recipharm in 2021, thereby freeing up significant capital for new investments. BioStock talked to Thomas Eldered about his investment strategy.Read the full article at biostock.se: https://www.biostock.se/en/2022/10/flerie-invest-invests-heavily-in-life-science/ This is a press release from BioStock -

Lindex is the fashion company of the year

Lindex is awarded the fashion company of the year by Market Awards. The jury’s motivation highlights that Lindex has dominated the market and clearly strengthened its position through exciting and innovative investments, clear customer focus and a successful work with both its physical stores and e-commerce. Photo: Pax Engström Nyström ’We are incredibly happy and proud of this fine award and appreciation. It is the prize of all Lindex employees who, with their great customer focus, fantastic commitment and wholehearted efforts, drive Lindex forward every day. We have had a

INVITATION: INVISIO invites you to a conference call October 28 at 10:00 CEST

INVISIO is pleased to invite press, investors and analysts to a conference call on October 28 at 10.00 CEST, where CEO Lars Højgård Hansen will present the Interim Report January-September 2022.The conference call, which will be held in English, will begin with a presentation of the report followed by a Q&A session. The report will be published on October 27, 2022, at 14:00 CEST. A replay of the call, the presentation and the Interim Report can be found on www.invisio.com.  Register for the conference To participate in the conference call, prior registration is required. After

Epiroc to acquire U.S. manufacturer of excavator attachments

Stockholm, Sweden: Epiroc, a leading productivity and sustainability partner for the mining and infrastructure industries, has agreed to acquire the business of Wain-Roy, a U.S. manufacturer of excavator attachments for the construction industry.The Wain-Roy business, with a manufacturing site in Kronenwetter, Wisconsin, United States, is part of Oregon Tool, Inc. The company’s customers are mainly in the United States. Wain-Roy has about 100 employees and annual revenues of about MSEK 200.  “Wain-Roy is known for its high-quality products and competence,” says Helena Hedblom, Epiroc’s

Nomination Committee appointed ahead of the 2023 Annual General Meeting

In accordance with the guidelines adopted by the Annual General Meeting on May 2, 2018, GARO has established a Nomination Committee. The Nomination Committee is to prepare and make proposals to the 2023 Annual General Meeting concerning: · the Chairman of the Annual General Meeting; · candidates for the post of Chairman and other members of the Board; · election and remuneration of the company’s auditors; · Board fees and distribution between the Chairman and other members as well as remuneration for committee work; and · any changes to the instructions for the Nomination

There are no items matching the current filter
There are no more items matching the current filter
Back to top